Bone Biologics Corporation
BBLGHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeBone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Valued at $1.1M, BBLG is a micro-cap name in its sector. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration.
Market Cap
$1.1M
Beta
0.57
P/E (TTM)
—
P/E (Fwd)
-0.59
EPS (TTM)
$-1.37
EPS (Fwd)
$-0.67
ROE
-55.0%
ROA
-33.5%
Cash
$4.0M
Total Debt
$0
Free CF
-$1.7M
52W Change
-81.7%
Annual Financials
Cash vs Debt
Where BBLG stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BBLG finished 59.41% below its 150-day moving average ($1.01) and 63.06% below its 200-day moving average ($1.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BBLG overbought or oversold?
At the October 20, 2026 close, BBLG's RSI(14) was 24.6, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Bone Biologics Corporation reports $4.0M in cash and $0 in total debt. Free cash flow is running at -$1.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -55.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.57 suggests BBLG is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BBLG.